MDxHealth S.A. (MDXH) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
MDxHealth S.A.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
364
First IPO Date
November 04, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Michael K. McGarrity | Chief Executive Officer & Executive Director | 899,424 | 1963 |
| Kim Leroux | Executive Vice President of Revenue Cycle Management | 0 | N/A |
| Scott McMahan | Vice President of Finance and Accounting | 0 | N/A |
| Joseph Sollee | Executive Vice President of Corporate Development & General Counsel | 0 | 1965 |
| Ron Kalfus | Interim Chief Financial Officer | 0 | 1974 |
| John A. Bellano | Chief Commercial Officer | 0 | 1969 |
Description
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
